PharmaSGP Holding SE PSG.F Stock
PharmaSGP Holding SE Price Chart
PharmaSGP Holding SE PSG.F Financial and Trading Overview
PharmaSGP Holding SE stock price | 23 EUR |
Previous Close | 28.2 EUR |
Open | 28 EUR |
Bid | 28.5 EUR x N/A |
Ask | 0 EUR x N/A |
Day's Range | 28.1 - 28.1 EUR |
52 Week Range | 22.5 - 29 EUR |
Volume | 40 EUR |
Avg. Volume | 29 EUR |
Market Cap | 337.2M EUR |
Beta (5Y Monthly) | -0.113761 |
PE Ratio (TTM) | 25.545454 |
EPS (TTM) | 1.25 EUR |
Forward Dividend & Yield | 0.49 (1.70%) |
Ex-Dividend Date | June 29, 2023 |
1y Target Est | N/A |
PSG.F Valuation Measures
Enterprise Value | 377.76M EUR |
Trailing P/E | 25.545454 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.7774317 |
Price/Book (mrq) | 9.982238 |
Enterprise Value/Revenue | 4.232 |
Enterprise Value/EBITDA | 13.266 |
Trading Information
PharmaSGP Holding SE Stock Price History
Beta (5Y Monthly) | -0.113761 |
52-Week Change | 23.24% |
S&P500 52-Week Change | 20.43% |
52 Week High | 29 EUR |
52 Week Low | 22.5 EUR |
50-Day Moving Average | 27.66 EUR |
200-Day Moving Average | 25.89 EUR |
PSG.F Share Statistics
Avg. Volume (3 month) | 29 EUR |
Avg. Daily Volume (10-Days) | 26 EUR |
Shares Outstanding | 12M |
Float | 2.36M |
Short Ratio | N/A |
% Held by Insiders | 80.10% |
% Held by Institutions | 11.48% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.49 |
Trailing Annual Dividend Yield | 1.73% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.4091 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 14.69% |
Operating Margin (ttm) | 22.19% |
Gross Margin | 90.03% |
EBITDA Margin | 31.90% |
Management Effectiveness
Return on Assets (ttm) | 9.79% |
Return on Equity (ttm) | 45.82% |
Income Statement
Revenue (ttm) | 89.27M EUR |
Revenue Per Share (ttm) | 7.46 EUR |
Quarterly Revenue Growth (yoy) | 16.69% |
Gross Profit (ttm) | 76.79M EUR |
EBITDA | 28.48M EUR |
Net Income Avi to Common (ttm) | 13.12M EUR |
Diluted EPS (ttm) | 1.1 |
Quarterly Earnings Growth (yoy) | 69.19% |
Balance Sheet
Total Cash (mrq) | 37.31M EUR |
Total Cash Per Share (mrq) | 3.15 EUR |
Total Debt (mrq) | 81.97M EUR |
Total Debt/Equity (mrq) | 245.59 EUR |
Current Ratio (mrq) | 2.338 |
Book Value Per Share (mrq) | 2.815 |
Cash Flow Statement
Operating Cash Flow (ttm) | 28.14M EUR |
Levered Free Cash Flow (ttm) | 21.3M EUR |
Profile of PharmaSGP Holding SE
Country | Germany |
State | N/A |
City | Gräfelfing |
Address | Lochhamer Schlag 21 |
ZIP | 82166 |
Phone | 49 89 85 89 639 |
Website | https://pharmasgp.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 79 |
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for treatment of hair loss; Dorisol, a pain relies tablet; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten, for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness and mood swings; Deruba, a cream for skin redness; Lentisol prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
Q&A For PharmaSGP Holding SE Stock
What is a current PSG.F stock price?
PharmaSGP Holding SE PSG.F stock price today per share is 23 EUR.
How to purchase PharmaSGP Holding SE stock?
You can buy PSG.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PharmaSGP Holding SE?
The stock symbol or ticker of PharmaSGP Holding SE is PSG.F.
Which industry does the PharmaSGP Holding SE company belong to?
The PharmaSGP Holding SE industry is Drug Manufacturers-Specialty & Generic.
How many shares does PharmaSGP Holding SE have in circulation?
The max supply of PharmaSGP Holding SE shares is 11.99M.
What is PharmaSGP Holding SE Price to Earnings Ratio (PE Ratio)?
PharmaSGP Holding SE PE Ratio is 18.40000000 now.
What was PharmaSGP Holding SE earnings per share over the trailing 12 months (TTM)?
PharmaSGP Holding SE EPS is 1.25 EUR over the trailing 12 months.
Which sector does the PharmaSGP Holding SE company belong to?
The PharmaSGP Holding SE sector is Healthcare.